[I" 'In] Somatostatin is a tetradecapeptide that has a wide range of biological activities functioning as a hormone releaseinhibitory factor, neurotransmitter, immunomodulator and endogenous inhibitor of cell growth (Mescardo & Sherline, 1982; Reichlin, 1983a,b; Vehmeyer et al., 1986; Malec et al., 1989) . Somatostatin acts by binding to specific receptors expressed by target tissues. Tumours with neuroendocrine features may express specific high-affinity binding sites for somatostatin .
Experimental studies have clearly demonstrated that the majority of small-cell lung cancer (SCLC) tumours are neuroendocrine. SCLC is characterised by the expression of both pan-neuroendocrine markers and specific hormones and their receptors, including bombesin/gastrin-releasing peptide (GRP) and insulin-like growth factor 1 (IGF-1) Moody et al., 1985; Macaulay et al., 1990; Macaulay & Carney, 1991; Sheppard, 1991) . Recent work has demonstrated that SCLC tumours may synthesise somatostatin and that between 50 and 75% have high-affinity somatostatin binding sites (Bepler et al., 1988; Taylor et al., 1988a; Bogden et al., 1990; Reubi et al., 1990b; Sagman et al., 1990; .
The radiolabelled somatostatin analogue ['231-tyr'] octreotide has been successfully used in scintigraphic imaging to detect neuroendocrine tumours, including gastrointestinal and pancreatic APUDomas and paragangliomas (Krenning et al., 1989; Lamberts et al., 1990a,b; Kwekkeboom et al., 1991) . However, it is an expensive preparation with very high hepatobiliary accumulation and a short effective half-life.
Furthermore, difficulties in labelling tyr'-octreotide with 1231 mean that such scans can only be performed in specialist centres. The newly developed preparation ["'In] pentetreotide, ["'In] diethylenetriaminopentaacetic (octreotide), may be prepared in any nuclear medicine department, is less expensive, is excreted predominantly by the kidney and has a long effective half-life (Krenning et al., 1992a) . Encouraging results have already been obtained with this analogue in imaging neuroendocrine tumours and lymphomas (Krenning et al., 1992a (Krenning et al., ,b, 1993 Van Hagen et al., 1993 (Minna et al., 1989) .
Following chemotherapy four patients were re-evaluated. A further patient with extensive disease, imaged with ["'In] pentetreotide after his first course of chemotherapy, was also assessed following completion of treatment.
The ["'In] pentetreotide, supplied by Mallinckrodt Medical (The Netherlands), was administered as an intravenous bolus injection. Prior to injection the pentetreotide was labelled with indium-111 as previously described (Krenning et al., 1992a) ["'I1n]PENTETREOTIDE SCLC IMAGING 763 and 245 keV, each with a 20% window. Images of the thorax and abdomen were obtained at 4 h. Images of the head and neck, thorax, abdomen and pelvis were obtained at 24 h.
The planar images were followed by single-photon emission computed tomographic (SPECT) acquisitions of the thorax and liver in a number of cases using an IGE 400 ACT gamma-camera employing an elliptical 360°orbit with 64 projections at 20 s per projection.
Results

Pretreatment assessment
Following standard staging six patients were found to have limited disease, while seven had extensive disease. Of those patients with extensive disease, four had liver metastases, four bony involvement, one a single large brain metastasis and one an adrenal metastasis.
Scintigraphic imaging with ["'In] pentetreotide led to the detection of all primary sites of disease. This included a patient in whom the primary tumour, detected at bronchoscopy, could not be visualised by other radiological techniques ( Figure 1 ).
In those patients with known extensive disease, patchy uptake within the liver, consistent with metastases, was noted in three of four patients and skeletal disease was detected in two of the four patients. The brain and adrenal metastases were not detected. In one patient a previously undetected brain metastasis was found which had not been suspected following routine staging ( Figure 2 ). This was later confirmed with a CT brain scan. As a result the patient was restaged as having extensive disease.
Scintigraphic imaging with ["'In] pentetreotide resulted in 9 of 13 patients being correctly staged (sensitivity 69%), detection of five of ten known metastatic and one previously unknown site (overall sensitivity 56%), down-staging of disease in four of seven patients with extensive disease and upstaging of disease in one patient with limited disease (Tables I and II) . Therefore, of the eight patients found to have metastases at the completion of all investigations, ["'In] ["l'In] pentetreotide scintigraphy revealed an area of pathological uptake in the region of the original disease (Figure 3 ). Subsequent magnetic resonance imaging confirmed the finding. As no histological proof of residual disease had been obtained it was decided to observe the patient only. The patient subsequently had a full clinical relapse of his disease at the primary site and developed intracerebral metastases, which were treated with palliative radiotherapy. He died 15 months after his initial diagnosis.
Case 2 A 34-year-old man with extensive disease was treated with six cycles of combination cisplatin and etoposide. Following treatment he was assessed as in case 1 together with an ultrasound of the abdomen but without bronchoscopy. CT of the thorax detected several nodules in the region of the original intrathoracic primary. These were Figure 1 Anterior image of the thorax 24 h post injection. Pathological uptake of the radiolabel is seen in the region of the left hilum (P) in keeping with the site of the small-cell lung tumour found at bronchoscopy. This tumour was not detectable using standard radiological methods. Non-specific uptake is seen in the thyroid (T), liver (L) and spleen (S). Pathological uptake of the radiolabel is noted in the region of the cerebellum (C) consistent with a metastasis. The apex of the primary intrathoracic tumour (P) is also seen. Non-specific uptake is noted in the thyroid gland (T). also detected with ["'In] (Table  III) . While non-specific, physiological accumulation of the radiolabel was noted in the spleen, kidneys and urinary tract, liver and gastrointestinal tract, pituitary and thyroid gland, no false-positive results were recorded (specificity 100%).
SPECT imaging improved the anatomical localisation of disease in the thorax but contributed little to the overall assessment.
Discussion
Small-cell lung cancer remains a disease with a poor prognosis despite being sensitive to both chemotherapy and radiotherapy. The median survival for patients with limited disease is in the region of 16 months with 5 year survival being achieved in 7-20% of patients. With extensive disease the median survival is 9 months with few long-term survivors. Therefore staging has a significant impact on prognosis and, in some cases, on the management of patients (Minna et al., 1989; Hansen, 1992) .
Recent experimental evidence suggests that neuroendocrine tumours may express receptors or high-affinity binding sites for somatostatin (Krenning et al., 1989 (Krenning et al., , 1992a Lamberts et al., 1990a,b; Kwekkeboom et al., 1991; Reubi et al., 1990a) . In vitro evidence suggests that between 50 and 75% of SCLC tumours have specific high-affinity binding sites for somatostatin (Taylor et al., 1988a; Bogden et al., 1990; Reubi et al., 1990b; Sagman et al., 1990; . Furthermore, SCLC disease sites were located in five of eight patients using [13I-tyr3]octreotide (Kwekkeboom et al., 1991) , while the primary sites of disease have been imaged in all patients evaluated with ["llIn]pentetreotide to date (Krenning et al., 1992b . This study is the first to evaluate ["'In] pentetreotide scintigraphy as a staging modality prior to chemotherapy and in the assessment of disease response after treatment. Our results substantiate earlier findings. In all cases the primary SCLC tumour was detected, including in one patient in whom Figure 3 Anterior views of the thorax 24 h post injection of a patient with limited stage disease small-cell lung cancer before and after completion of treatment. The pretreatment image on the left shows disease in the right perihilar region. The post-therapy image is shown on the right. A small area of residual disease is noted in the same area. This could not be detected with standard staging methods. Non-specific uptake is noted in the liver (L), spleen (S) and kidneys (K).
["'In]PENTETREOTIDE SCLC IMAGING 765 primary site, detected at bronchoscopy, could not be visualised with standard radiological techniques.
All sites of metastatic disease were visualised in 50% of the patients with extensive disease at the completion of all investigations. This included one patient in whom a previously unsuspected cerebellar metastasis was localised. This resulted in restaging of his disease from limited disease to extensive disease.
The detection of the intracranial metastasis raises the question as to whether or not CT brain scanning should be routine in the assessment of patients with presumed limited SCLC prior to treatment. Several studies have demonstrated that the detection rate of asymptomatic brain metastases is low -in the region of 10% of all new cases of SCLC. Furthermore, current evidence suggests that patients with brain metastases as the only site of extensive disease have a median survival not markedly different from that of patients with limited disease, although long-term survival is rare (Minna et al., 1989; Hardy et al., 1990) . Therefore, at the present time, routine CT brain scanning at presentation is not recommended in patients without other clinical evidence of intracranial disease.
Following staging all patients received etoposide-based chemotherapy in combination with doxorubicin and cyclophosphamide or cisplatin or carboplatin. The patient with the cerebellar metastasis detected by ["'11n] pentetreotide imaging received cranial irradiation as well as systemic carboplatin and etoposide chemotherapy.
["'In]pentetreotide imaging proved more effective than conventional staging methods in detecting residual intrathoracic disease following completion of treatment, localising sites of disease in two patients otherwise thought to be in complete remission. Therefore, the technique appears to allow a more accurate assessment of prognosis to be made in an individual patient following completion of therapy and may aid subsequent management decisions. Use of this imaging modality may be of particular importance in the evaluation of the response of SCLC tumours to novel forms of treatment.
The reason for non-visualisation of the metastases in 50% of cases is unclear. Non-specific uptake of the radiolabel seen in the spleen, kidneys and urinary tract, liver and gastrointestinal tract, pituitary and thyroid gland may obscure visualisation of metastases to these areas. However, the lack of uptake of radiolabel by bone and brain deposits cannot be explained in this way. This raises a number of possibilities. In a proportion of cases the metastatic disease may represent a dedifferentiated clone of the primary SCLC tumour not expressing somatostatin receptors. Local factors may also be playing a role in individual patients either by downregulating somatostatin receptor expression or, if high local levels of endogenous somatostatin are being produced, by blocking the receptor site, thereby inhibiting visualisation of the disease. Finally, in image-negative metastatic disease it is possible that the SCLC cells themselves are not expressing specific somatostatin binding sites. Rather it may be that the primary tumour is being visualised because of uptake of the radiolabel by the local inflammatory response, as activated immune cells are known to express somatostatin receptors (Nakamura et al., 1987; Sreedharan et al., 1989) . If this were the case then those patients in whom the metastases are seen may represent the true proportion of patients with metastatic SCLC tumours that express high-affinity binding sites for somatostatin -50% of patients with extensive disease evaluated in this study. This would be in keeping with the known in vitro data.
Novel approaches to therapy in SCLC are currently being assessed and include inhibiting the action of autocrine growth factors such as GRP with GRP antagonists and GRP receptor antibodies (Cuttitta et al., 1987; Macaulay & Carney, 1991; Carney, 1992 (Taylor et al., 1988b (Taylor et al., , 1991 . The growth of SCLC xenografts has been inhibited in athymic nude mice (Taylor et al., 1988b; Bogden et al., 1990; . These results suggest that SCLC somatostatin receptors are functional and that the growth-inhibitory effect is direct through inhibition of specific growth pathways within the tumour cells. Somatostatin analogues may also have indirect growthinhibitory effects through the inhibition of growth factors released from other tissues, such as IGF-1 and epidermal growth factor (Ghirlanda et al., 1983; Damstrup et al., 1992 The possibility of using radiolabelled antibodies to treat a wide range of tumours has yielded interesting data (Larson, 1987; Goldenberg, 1991) . However, one of the principal problems encountered includes the generation of host antibody response to the administered agent rendering the radiolabel useless (Goldenberg, 1991) . The possibility of employing a radiolabelled chelated somatostatin analogue as a radiotherapeutic agent in treating somatostatin receptor-positive SCLC tumours is an exciting prospect for the future. As somatostatin analogues are based on sequences of host circulating hormone they rarely induce immunisation ). The accumulation of ["'In] pentetreotide in gastrointestinal APUDomas is between 0.0123% and 0.2% of the administered dose per gram of tumour tissue. The rapid clearance of the radiolabel from the blood, the relatively low accumulation in the liver (1.9% and 2.2% of the administered dose at 4 and 24 h respectively) with resultant relatively low excretion into the gastrointestinal tract, and, finally, the predominant renal clearance are advantageous in this regard.
However, the amount of renal accumulation and the relatively long renal effective half-life will limit the maximally applicable radiation dose. Studies are required to investigate how to lower the renal radioactivity 
